The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
α-Synuclein and dopamine at the crossroads of Parkinson's disease
Open accessAbstract
α-Synuclein is central to the Lewy body neuropathology of Parkinson’s disease (PD), a devastating neurodegenerative disorder characterized by numerous motor and non-motor manifestations. The cardinal motor symptoms are linked to death of dopaminergic neurons in the nigrostriatal pathway. Here we ask why these neurons are preferentially susceptible to neurodegeneration in PD and how α-synuclein is involved. To address these questions we bring together recent findings from genome-wide association studies, which reveal the involvement of α-synuclein gene variants in sporadic PD, with recent studies highlighting important roles for α-synuclein in synaptic transmission and dopaminergic neuron physiology. These latest advances add to our understanding of PD etiology and provide a central link between the genetic findings and neurodegeneration observed in sporadic PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“The first genetic evidence for the involvement of the α-synuclein gene, SNCA, in PD was the identification of three missense mutations (A30P, E46K and A53T) which segregated with the disease in unrelated families and caused PD with high penetrance [8–10].”
Backgroundα-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
AGEING AND PARKINSON'S DISEASE: SUBSTANTIA NIGRA REGIONAL SELECTIVITY
FEARNLEY, J. M., & LEES, A. J. (1991) · Brain · doi:10.1093/brain/114.5.2283 · Cited by 3,529
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
Oxidative stress in Parkinson's disease
Jenner, P. (2003) · Annals of Neurology · doi:10.1002/ana.10483 · Cited by 2,053
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,953
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Genome-wide association study reveals genetic risk underlying Parkinson's disease
Simón-Sánchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., Paisan-Ruiz, C., Lichtner, P., Scholz, S. W., Hernandez, D. G., et al. (2009) · Nature Genetics · doi:10.1038/ng.487 · Cited by 1,751
Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
Caughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650 · cited 1×
“A widely accepted hypothesis for α-synuclein toxicity proposes that protofibrils of α-synuclein are cytotoxic, whereas the fibrillar aggregates of the protein could represent a cytoprotective mechanism in PD [97,98].”
Background(1998) · Europe PMC (PubMed Central) · Cited by 1,594
Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes
Davidson, W. S., Jonas, A., Clayton, D. F., & George, J. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.16.9443 · Cited by 1,585
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570
Giasson, B. I., Duda, J. E., Murray, I. V. J., Chen, Q., Souza, J. M., Hurtig, H. I., Ischiropoulos, H., Trojanowski, J. Q., & -Y. Lee, V. M. (2000) · Science · doi:10.1126/science.290.5493.985 · Cited by 1,546
Conway, K. A., Lee, S.-J., Rochet, J.-C., Ding, T. T., Williamson, R. E., & Lansbury, P. T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.571 · Cited by 1,541
Anderson, J. P., Walker, D. E., Goldstein, J. M., de Laat, R., Banducci, K., Caccavello, R. J., Barbour, R., Huang, J., Kling, K., Lee, M., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600933200 · Cited by 1,416
α-Synuclein Blocks ER-Golgi Traffic and Rab1 Rescues Neuron Loss in Parkinson's Models
Cooper, A. A., Gitler, A. D., Cashikar, A., Haynes, C. M., Hill, K. J., Bhullar, B., Liu, K., Xu, K., Strathearn, K. E., Liu, F., et al. (2006) · Science · doi:10.1126/science.1129462 · Cited by 1,376
Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., Kawaguchi, T., Tsunoda, T., Watanabe, M., Takeda, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.485 · Cited by 1,324
Samii, A., Nutt, J. G., & Ransom, B. R. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16305-8 · Cited by 1,265
Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
Conway, K. A., Rochet, J.-C., Bieganski, R. M., & Lansbury, P. T. (2001) · Science · doi:10.1126/science.1063522 · Cited by 1,127
Giasson, B. I., Murray, I. V. J., Trojanowski, J. Q., & Lee, V. M.-Y. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008919200 · Cited by 1,080
Nemani, V. M., Lu, W., Berge, V., Nakamura, K., Onoa, B., Lee, M. K., Chaudhry, F. A., Nicoll, R. A., & Edwards, R. H. (2010) · Neuron · doi:10.1016/j.neuron.2009.12.023 · Cited by 1,056
Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease
Ibáñez, P., Bonnet, A.-M., Débarges, B., Lohmann, E., Tison, F., Agid, Y., Dürr, A., Brice, A., & Pollak, P. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17104-3 · Cited by 1,044
α-Synuclein Cooperates with CSPα in Preventing Neurodegeneration
Chandra, S., Gallardo, G., Fernández-Chacón, R., Schlüter, O. M., & Südhof, T. C. (2005) · Cell · doi:10.1016/j.cell.2005.09.028 · Cited by 966
‘Rejuvenation’ protects neurons in mouse models of Parkinson’s disease
Chan, C. S., Guzman, J. N., Ilijic, E., Mercer, J. N., Rick, C., Tkatch, T., Meredith, G. E., & Surmeier, D. J. (2007) · Nature · doi:10.1038/nature05865 · Cited by 904
Kraytsberg, Y., Kudryavtseva, E., McKee, A. C., Geula, C., Kowall, N. W., & Khrapko, K. (2006) · Nature Genetics · doi:10.1038/ng1778 · Cited by 887
Cabin, D. E., Shimazu, K., Murphy, D., Cole, N. B., Gottschalk, W., McIlwain, K. L., Orrison, B., Chen, A., Ellis, C. E., Paylor, R., et al. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-08797.2002 · Cited by 865
Matsuda, W., Furuta, T., Nakamura, K. C., Hioki, H., Fujiyama, F., Arai, R., & Kaneko, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4029-08.2009 · Cited by 865
Murphy, D. D., Rueter, S. M., Trojanowski, J. Q., & Lee, V. M.-Y. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-09-03214.2000 · Cited by 836
Repression of α-synuclein expression and toxicity by microRNA-7
Junn, E., Lee, K.-W., Jeong, B. S., Chan, T. W., Im, J.-Y., & Mouradian, M. M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906277106 · Cited by 655 · cited 1×
“The 3′-UTR of SNCA is known to contain target binding sites for two microRNAs, mir-7 and mir-153, which are expressed predominantly in neurons and induce downregulation of α-synuclein expression [32,33].”
BackgroundKirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T. E., Muzyczka, N., Mandel, R. J., & Björklund, A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02780.2002 · Cited by 649
(2004) · doi:10.1002/ana.10846 · Cited by 614
A Role for α-Synuclein in the Regulation of Dopamine Biosynthesis
Perez, R. G., Waymire, J. C., Lin, E., Liu, J. J., Guo, F., & Zigmond, M. J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03090.2002 · Cited by 598 · cited 3×
“α-Synuclein has been shown to regulate the production of dopamine in cultured cells through its interaction with tyrosine hydroxylase (TH), the rate-limiting enzyme responsible for converting tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA) in the dopamine synthesis pathway [35,36] (Figure 2).”
BackgroundMultiple hit hypotheses for dopamine neuron loss in Parkinson's disease
Sulzer, D. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.009 · Cited by 587
Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP
Dauer, W., Kholodilov, N., Vila, M., Trillat, A.-C., Goodchild, R., Larsen, K. E., Staal, R., Tieu, K., Schmitz, Y., Yuan, C. A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172514599 · Cited by 581
The substantia nigra of the human brain
Damier, P., Hirsch, E. C., Agid, Y., & Graybiel, A. M. (1999) · Brain · doi:10.1093/brain/122.8.1421 · Cited by 578
Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation
Uversky, V. N. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04764.x · Cited by 567
Sharon, R., Bar-Joseph, I., Frosch, M. P., Walsh, D. M., Hamilton, J. A., & Selkoe, D. J. (2003) · Neuron · doi:10.1016/s0896-6273(03)00024-2 · Cited by 562
Mosharov, E. V., Larsen, K. E., Kanter, E., Phillips, K. A., Wilson, K., Schmitz, Y., Krantz, D. E., Kobayashi, K., Edwards, R. H., & Sulzer, D. (2009) · Neuron · doi:10.1016/j.neuron.2009.01.033 · Cited by 534
The Parkinson's disease protein α-synuclein disrupts cellular Rab homeostasis
Gitler, A. D., Bevis, B. J., Shorter, J., Strathearn, K. E., Hamamichi, S., Su, L. J., Caldwell, K. A., Caldwell, G. A., Rochet, J.-C., McCaffery, J. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710685105 · Cited by 523
Collaborative Analysis of α-Synuclein Gene Promoter Variability and Parkinson Disease
Maraganore, D. M. (2006) · JAMA · doi:10.1001/jama.296.6.661 · Cited by 508
Oorschot, D. E. (1996) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19960318)366:4<580::aid-cne3>3.0.co;2-0 · Cited by 499
Edwards, T. L., Scott, W. K., Almonte, C., Burt, A., Powell, E. H., Beecham, G. W., Wang, L., Züchner, S., Konidari, I., Wang, G., et al. (2010) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2009.00560.x · Cited by 465
LEE, F. J. S., LIU, F., PRISTUPA, Z. B., & NIZNIK, H. B. (2001) · The FASEB Journal · doi:10.1096/fj.00-0334com · Cited by 455
Post-transcriptional Regulation of α-Synuclein Expression by mir-7 and mir-153
Doxakis, E. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.086827 · Cited by 454
Mendez, I., Sanchez-Pernaute, R., Cooper, O., Viñuela, A., Ferrari, D., Björklund, L., Dagher, A., & Isacson, O. (2005) · Brain · doi:10.1093/brain/awh510 · Cited by 438
Volles, M. J., & Lansbury, P. T. (2003) · Biochemistry · doi:10.1021/bi030086j · Cited by 433
Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro
Hashimoto, M., Hsu, L. J., Xia, Y., Takeda, A., Sisk, A., Sundsmo, M., & Masliah, E. (1999) · NeuroReport · doi:10.1097/00001756-199903170-00011 · Cited by 429
Synthetic filaments assembled from C‐terminally truncated α‐synuclein
Crowther, R. A., Jakes, R., Spillantini, M. G., & Goedert, M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01146-6 · Cited by 417
Larsen, K. E., Schmitz, Y., Troyer, M. D., Mosharov, E., Dietrich, P., Quazi, A. Z., Savalle, M., Nemani, V., Chaudhry, F. A., Edwards, R. H., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3821-06.2006 · Cited by 415
Neuhoff, H., Neu, A., Liss, B., & Roeper, J. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-04-01290.2002 · Cited by 398
Dopamine transporters and neuronal injury
Miller, G. W., Gainetdinov, R. R., Levey, A. I., & Caron, M. G. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01379-6 · Cited by 371
Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro
Murray, I. V. J., Giasson, B. I., Quinn, S. M., Koppaka, V., Axelsen, P. H., Ischiropoulos, H., Trojanowski, J. Q., & Lee, V. M.-Y. (2003) · Biochemistry · doi:10.1021/bi027363r · Cited by 365
Chung, C. Y., Seo, H., Sonntag, K. C., Brooks, A., Lin, L., & Isacson, O. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi178 · Cited by 361
Monte, D. A. D. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00501-5 · Cited by 361
α-Synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication
Miller, D. W., Hague, S. M., Clarimon, J., Baptista, M., Gwinn-Hardy, K., Cookson, M. R., & Singleton, A. B. (2004) · Neurology · doi:10.1212/01.wnl.0000127517.33208.f4 · Cited by 356
Wolfart, J., Neuhoff, H., Franz, O., & Roeper, J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-10-03443.2001 · Cited by 345
alpha-synuclein gene haplotypes are associated with Parkinson's disease
Farrer, M. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.17.1847 · Cited by 340
Role of α-Synuclein in Presynaptic Dopamine Recruitment
Yavich, L., Tanila, H., Vepsäläinen, S., & Jäkälä, P. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2559-04.2004 · Cited by 316
K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons
Liss, B., Haeckel, O., Wildmann, J., Miki, T., Seino, S., & Roeper, J. (2005) · Nature Neuroscience · doi:10.1038/nn1570 · Cited by 299
Calcium, ageing, and neuronal vulnerability in Parkinson's disease
Surmeier, D. J. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70246-6 · Cited by 297
Gosavi, N., Lee, H.-J., Lee, J. S., Patel, S., & Lee, S.-J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208194200 · Cited by 294
Molecular pathogenesis of Parkinson disease: insights from genetic studies
Gasser, T. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001148 · Cited by 290
Arbuthnott, G. W., & Wickens, J. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2006.12.003 · Cited by 274
Neuropathology of non-motor features of Parkinson disease
Dickson, D. W., Fujishiro, H., Orr, C., DelleDonne, A., Josephs, K. A., Frigerio, R., Burnett, M., Parisi, J. E., Klos, K. J., & Ahlskog, J. E. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70769-2 · Cited by 266
Part II: α-synuclein and its molecular pathophysiological role in neurodegenerative disease
Dev, K. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00140-0 · Cited by 263
Peng, X. M., Tehranian, R., Dietrich, P., Stefanis, L., & Perez, R. G. (2005) · Journal of Cell Science · doi:10.1242/jcs.02481 · Cited by 249 · cited 1×
“In addition, α-synuclein has been shown to bind TH, preventing its phosphorylation and inhibiting its activation by promoting the activity of protein phosphatase 2A (PP2A) [35,40].”
BackgroundGenetic variability in the SNCA gene influences α‐synuclein levels in the blood and brain
Fuchs, J., Tichopad, A., Golub, Y., Munz, M., Schweitzer, K. J., Wolf, B., Berg, D., Mueller, J. C., & Gasser, T. (2008) · The FASEB Journal · doi:10.1096/fj.07-9348com · Cited by 247
Exley, R., Clements, M. A., Hartung, H., McIntosh, J. M., & Cragg, S. J. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301617 · Cited by 242
Self-citationChiba-Falek, O. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.26.3101 · Cited by 242
Role of Cytochrome c as a Stimulator of α-Synuclein Aggregation in Lewy Body Disease
Hashimoto, M., Takeda, A., Hsu, L. J., Takenouchi, T., & Masliah, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.41.28849 · Cited by 236
Threlfell, S., Clements, M. A., Khodai, T., Pienaar, I. S., Exley, R., Wess, J., & Cragg, S. J. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5620-09.2010 · Cited by 224
Self-citationRichardson, J. R., Caudle, W. M., Wang, M., Dean, E. D., Pennell, K. D., Miller, G. W., Richardson, J. R., Caudle, W. M., Wang, M., Dean, E. D., et al. (2006) · The FASEB Journal · doi:10.1096/fj.06-5864fje · Cited by 216
In Vivo RNAi-Mediated α-Synuclein Silencing Induces Nigrostriatal Degeneration
Gorbatyuk, O. S., Li, S., Nash, K., Gorbatyuk, M., Lewin, A. S., Sullivan, L. F., Mandel, R. J., Chen, W., Meyers, C., Manfredsson, F. P., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.115 · Cited by 213
α‐Synuclein promoter confers susceptibility to Parkinson's disease
Pals, P., Lincoln, S., Manning, J., Heckman, M., Skipper, L., Hulihan, M., Van den Broeck, M., De Pooter, T., Cras, P., Crook, J., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20268 · Cited by 212
Beyer, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0104-6 · Cited by 209
Attenuation of dopamine transporter activity by α-synuclein
Wersinger, C., & Sidhu, A. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00097-1 · Cited by 197
Neuronal vulnerability in Parkinson’s disease
Hirsch, E. C., Faucheux, B., Damier, P., Mouatt-Prigent, A., & Agid, Y. (1997) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-6842-4_9 · Cited by 192
Levels of alpha‐synuclein mRNA in sporadic Parkinson disease patients
Chiba‐Falek, O., Lopez, G. J., & Nussbaum, R. L. (2006) · Movement Disorders · doi:10.1002/mds.21007 · Cited by 164
Senior, S. L., Ninkina, N., Deacon, R., Bannerman, D., Buchman, V. L., Cragg, S. J., & Wade‐Martins, R. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06055.x · Cited by 164
Self-citationNon-motor extranigral signs and symptoms in Parkinson's disease
Wolters, E. C. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70770-9 · Cited by 163
Role of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice
Schlüter, O. M., Fornai, F., Alessandri, M., TAKAMORI, S., Geppert, M., Jahn, R., & Südhof, T. C. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00036-8 · Cited by 159
Wakamatsu, M., Ishii, A., Iwata, S., Sakagami, J., Ukai, Y., Ono, M., Kanbe, D., Muramatsu, S.-I., Kobayashi, K., Iwatsubo, T., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.017 · Cited by 158
Robertson, D. C., Schmidt, O., Ninkina, N. N., Jones, P. A., Sharkey, J., & Buchman, V. L. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02378.x · Cited by 156
Self-citationBaptista, M. J., O’Farrell, C., Daya, S., Ahmad, R., Miller, D. W., Hardy, J., Farrer, M. J., & Cookson, M. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01742.x · Cited by 154
Fountaine, T. M., & Wade‐Martins, R. (2006) · Journal of Neuroscience Research · doi:10.1002/jnr.21125 · Cited by 145
Self-citationCragg, S. J. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-10-04378.2003 · Cited by 139
Self-citationGenetic studies in Alzheimer's disease with an NACP/α‐synuclein polymorphism
Xia, Y., de Silva, H. A. R., Rosi, B. L., Yamaoka, L. H., Rimmler, J. B., Pericak‐Vance, M. A., Roses, A. D., Chen, X., Masliah, E., DeTeresa, R. M., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410400212 · Cited by 133
Touchman, J. W., Dehejia, A. M., Chiba‐Falek, O., Cabin, D. E., Schwartz, J. R., Orrison, B. M., Polymeropoulos, M. H., & Nussbaum, R. L. (2001) · Genome Research · doi:10.1101/gr.165801 · Cited by 133
Al-Wandi, A., Ninkina, N. N., Millership, S. J., Williamson, S. J. M., Jones, P. A., & Buchman, V. L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.11.001 · Cited by 132
Self-citationUhl, G. R. (1998) · Annals of Neurology · doi:10.1002/ana.410430503 · Cited by 130
Alpha‐synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells
Tehranian, R., Montoya, S. E., Laar, A. D. V., Hastings, T. G., & Perez, R. G. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04146.x · Cited by 128
Inhibition of tyrosine hydroxylase expression in α-synuclein-transfected dopaminergic neuronal cells
Yu, S., Zuo, X., Li, Y., Zhang, C., Zhou, M., Zhang, Y. A., Uéda, K., & Chan, P. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.05.118 · Cited by 123
Cronin, K. D., Ge, D., Manninger, P., Linnertz, C. L., Rossoshek, A., Orrison, B. M., Bernard, D. J., El‐Agnaf, O. M. A., Schlossmacher, M. G., Nussbaum, R. L., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp265 · Cited by 123
Genome-wide association studies: the key to unlocking neurodegeneration?
Gandhi, S., & Wood, N. W. (2010) · Nature Neuroscience · doi:10.1038/nn.2584 · Cited by 113
Yavich, L., Oksman, M., Tanila, H., Kerokoski, P., Hiltunen, M. O., van Groen, T., Puoliväli, J. T., Männistö, P. T., Garcia-Horsman, A., MacDonald, E., et al. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.010 · Cited by 112
Alteration in α‐synuclein mRNA expression in Parkinson's disease
Kingsbury, A. E., Daniel, S. E., Sangha, H., Eisen, S., Lees, A. J., & Foster, O. J. F. (2003) · Movement Disorders · doi:10.1002/mds.10683 · Cited by 103
Alerte, T. N. M., Akinfolarin, A. A., Friedrich, E. E., Mader, S. A., Hong, C.-S., & Perez, R. G. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.02.014 · Cited by 98
The effect of α‐synuclein knockdown on MPP+ toxicity in models of human neurons
Fountaine, T. M., Venda, L. L., Warrick, N., Christian, H., Brundin, P., Channon, K. M., & Wade‐Martins, R. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06527.x · Cited by 90
Self-citationA marked rise in 5-S-cysteinyl-dopamine levels in guinea-pig striatum following reserpine treatment
Fornstedt, B., & Carlsson, A. (1989) · Journal of Neural Transmission · doi:10.1007/bf01578755 · Cited by 74
Silencing α-Synuclein Gene Expression Enhances Tyrosine Hydroxylase Activity in MN9D Cells
Liu, D., Jin, L., Wang, H., Zhao, H., Zhao, C., Duan, C., Lu, L., Wu, B., Yu, S., Chan, P., et al. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9599-7 · Cited by 65
Oxidants induce alternative splicing of α-synuclein: Implications for Parkinson's disease
Kalivendi, S. V., Yedlapudi, D., Hillard, C. J., & Kalyanaraman, B. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.10.045 · Cited by 60
Liss, B., Neu, A. D., & Roeper, J. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-20-08839.1999 · Cited by 60
The ups and downs of α‐synuclein mRNA expression
Dächsel, J. C., Lincoln, S., Gonzalez, J., Ross, O. A., Dickson, D. W., & Farrer, M. J. (2006) · Movement Disorders · doi:10.1002/mds.21223 · Cited by 54
Buchman, V. L., & Ninkina, N. N. (2008) · Neurotoxicity Research · doi:10.1007/bf03033857 · Cited by 34
Self-citationEffect of α-synuclein on the promoter activity of tyrosine hydroxylase gene
Gao, N., Li, Y., Li, X., Yu, S., Fu, G., & Chen, B. (2007) · Neuroscience Bulletin · doi:10.1007/s12264-007-0008-z · Cited by 30
Cited by
Exner, N., Lutz, A. K., Haass, C., & Winklhofer, K. F. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.170 · Cited by 642
Savelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581
Parkinson’s Disease: Biomarkers, Treatment, and Risk Factors
Emamzadeh, F. N., & Surguchov, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00612 · Cited by 568
Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
Jellinger, K. A. (2012) · Movement Disorders · doi:10.1002/mds.23795 · Cited by 451
Modeling Parkinson’s Disease With the Alpha-Synuclein Protein
Gómez-Benito, M., Granado, N., García-Sanz, P., Michel, A., Dumoulin, M., & Moratalla, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00356 · Cited by 437
Metadata
- Authors
- Venda, L. L., Cragg, S. J., Buchman, V. L., & Wade-Martins, R.
- Venue
- Trends in Neurosciences
- Publisher
- Elsevier BV
- Published
- 2010-12
- Volume
- 33
- Issue
- 12
- Pages
- 559-568
- ISSN
- 0166-2236 (ISSN-L)
- OpenAlex
- W1970826466
- Cited by
- 285
- References
- 109
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.